The French glioblastoma biobank (FGB): a national clinicobiological database

Anne Clavreul (1, 2) , Gwénaëlle Soulard (1, 2) , Jean-Michel Lemée (1, 2) , Marion Rigot (3) , Pascale Fabbro-Peray (4, 5) , Luc Bauchet (6) , Dominique Figarella-Branger (7, 8) , Philippe Menei (1, 2)

1 CHU Angers - Centre Hospitalier Universitaire d'Angers
2 CRCINA-ÉQUIPE 17 - Design and Application of Innovative Local Treatments in Glioblastoma
3 CHU Nantes - Centre Hospitalier Universitaire de Nantes
4 CHU Nîmes - Centre Hospitalier Universitaire de Nîmes
5 AIDMP - Aide à la Décision pour une Médecine Personnalisé - Laboratoire de Biostatistique, Epidémiologie et Recherche Clinique - EA 2415
6 INM - Institut des Neurosciences de Montpellier
7 INP - Institut de neurophysiopathologie
8 AMU - Aix Marseille Université

Background. Glioblastomas (GB) are the most common and lethal primary brain tumors. Significant progress has been made toward identifying potential risk factors for GB and diagnostic and prognostic biomarkers. However, the current standard of care for newly diagnosed GB, the Stupp protocol, has remained unchanged for over a decade. Large-scale translational programs based on a large clinicobiological database are required to improve our understanding of GB biology, potentially facilitating the development of personalized and specifically targeted therapies. With this goal in mind, a well-annotated clinicobiological database housing data and samples from GB patients has been set up in France: the French GB biobank (FGB). Methods. The biobank contains data and samples from adult GB patients from 24 centers in France providing written informed consent. Clinical and biomaterial data are stored in anonymized certified electronic case report forms. Biological samples (including frozen and formalin-fixed paraffin-embedded tumor tissues, blood samples, and hair) are conserved in certified biological resource centers or tumor tissue banks at each participating center. Results. Clinical data and biological materials have been collected for 1087 GB patients. A complete set of samples (tumor, blood and hair) is available for 66%, and at least one frozen tumor sample is available for 88% of the GB patients.ConclusionsThis large biobank is unique in Europe and can support the large-scale translational projects required to improve GB care. Additional biological materials, such as peritumoral brain zone and fecal samples, will be collected in the future, to respond to research needs.

Mots clés: Glioblastoma; Biobank; Biological materials; Database; Clinical data

Domaines: Cancer

Anne Clavreul, Gwénaëlle Soulard, Jean-Michel Lemée, Marion Rigot, Pascale Fabbro-Peray, et al.. The French glioblastoma biobank (FGB): a national clinicobiological database. Journal of Translational Medicine, 2019, 17 (1), pp.133. ⟨10.1186/s12967-019-1859-6⟩. ⟨hal-02156158⟩